Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Vahdat LT, et al. Among authors: joy aa. Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20. Oncologist. 2017. PMID: 28220020 Free PMC article. Clinical Trial.
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, Iscoe N, Gelmon K. Clemons M, et al. Among authors: joy aa. Breast Cancer Res Treat. 2010 Nov;124(1):177-86. doi: 10.1007/s10549-010-1152-0. Epub 2010 Sep 3. Breast Cancer Res Treat. 2010. PMID: 20814815 Clinical Trial.
Targeting HER2 in Advanced Breast Cancer.
Zhu X, Joy AA. Zhu X, et al. Among authors: joy aa. Methods Mol Biol. 2017;1652:63-77. doi: 10.1007/978-1-4939-7219-7_4. Methods Mol Biol. 2017. PMID: 28791634 Review.
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. Diéras V, et al. Among authors: joy aa. Oncologist. 2019 Dec;24(12):1514-1525. doi: 10.1634/theoncologist.2019-0019. Epub 2019 Jun 19. Oncologist. 2019. PMID: 31217344 Free PMC article. Clinical Trial.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Gelmon KA, et al. Among authors: joy aa. Breast J. 2020 Mar;26(3):368-375. doi: 10.1111/tbj.13516. Epub 2019 Aug 25. Breast J. 2020. PMID: 31448513 Free PMC article. Clinical Trial.
Frequency, Timing, and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data.
Watanabe SM, Faily V, Mawani A, Huot A, Tarumi Y, Potapov A, Fassbender K, Fairchild A, Joy AA, King KM, Roa W, Venner CP, Baracos VE. Watanabe SM, et al. Among authors: joy aa. Oncologist. 2020 Aug;25(8):722-728. doi: 10.1634/theoncologist.2019-0384. Epub 2020 Jun 9. Oncologist. 2020. PMID: 32445194 Free PMC article.
132 results